Skip to main content

Posts tagged with "Uncategorized"

  • More Small Molecule Clinical Data Against Covid-19, As of April 16

    There are several clinical trial updates for today – some that have reported data, and two that are apparently never going to report at all. I refer to trials of Gilead’s remdesivir in China, one for moderate cases and one for severe ones, both of which were updated yesterday to “suspended” on That took… Read More
  • More Therapeutic Ideas for the Coronavirus: Too Much Inflammation?

    So today I’d like to talk about some of the other anti-coronativirus possibilities that I haven’t gone into yet – these posts will never make a comprehensive list, but at least I can cover some of the more interesting ideas, I hope. Interleukin-6 is an interesting story. This preprint from German researchers presents some evidence… Read More
  • Known Drugs Being Tried Against the Coronavirus: Runner-Up Candidates

    Everyone’s heard plenty about chloroquine, azithromycin, remdesivir and other front-running ideas for anti-coronovirus therapies. Today I wanted to focus on some compounds that haven’t gotten as much attention but which have been proposed from more than one place as possibilities. Some of these have shown up in the comments to past post… Read More
  • Clinical Trials

    Adaptive Trials

    There are a lot of clinical trial designs out there. But one thing that a lot of them have in common is that they are designed right from the start to run under certain set conditions and to enroll a set number of people (or at least to meet certain thresholds before that enrollment is… Read More
  • Don’t Let Humans Pick the Experimental Conditions?

    When chemists have a wide range of reactants to choose from to make new compounds, how do they choose which ones to use? “Not randomly” is the answer, even when perhaps it should be. This effect has been noted in medicinal chemistry, where the choice of building blocks (not to mention reactions) for analog synthesis… Read More
  • Business and Markets

    The Last of Stemcentrx

    The final implosion of the Stemcentrx deal is worth a note, although I said a lot of what I have to say about it back in December. I want to especially emphasize two points I made back then – first, that the failure of this whole acquisition is different only in degree, and not in… Read More
  • Sweet Almonds: One Amino Acid Did the Trick

    Well, I spent the holiday weekend here sending out pictures of food on my Twitter account, so I suppose it’s only fitting that I blog about a related topic today. But it also touches on metabolic enzymes, transcription factors, and death by cyanide, so there’s something for most everyone. I refer to this paper which… Read More
  • Fast Pain Relief – In Only Seven Million Years

    Here’s a chemical descriptor that I didn’t know: algogen, meaning a molecule that causes pain. I would have classified the natural product I did my PhD work on as one, since it caused me substantial pain at the time, but this term refers more properly to physical nociceptive types of pain, rather than the intellectual… Read More
  • Animal Testing

    Autism Mouse Models for the Microbiome?

    Many readers will have seen the paper that just came out on a possible mouse-model demonstration of a connection between autism and the gut microbiome. It’s certainly generated a lot of headlines, and its very title guaranteed that it would: “Human Gut Microbiota from Autism Spectrum Disorder Promote Behavioral Symptoms in Mice“.… Read More
  • Aging and Lifespan

    VCAM1 As a Player in the Aging Brain

    Possible intervention targets for age-related degeneration are always welcome, particularly when they come bearing experimental evidence, and even more so when they relate to the central nervous system. That’s the case with this new paper, from a multicenter team led out of Stanford. Interestingly, this also ties in with the well-publicized … Read More